Explore Our Network

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

This organization specializes in integrated, science-based treatment and diagnostics for Alzheimer’s, dementia, and cognitive decline. Utilizing a precision medicine approach, the center combines advanced AI analysis, biomarker-driven planning, and multimodal therapies including brain imaging, neurocognitive testing, and over 50 clinical and supportive treatment modalities. The care model addresses both the root causes and neuropsychiatric aspects of cognitive impairment, delivered by a multidisciplinary team with expertise in functional, regenerative, and collaborative behavioral medicine.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

BioBridge Global is a nonprofit organization dedicated to saving and enhancing lives through the healing power of human cells and tissue. It operates a family of nonprofits including South Texas Blood & Tissue, QualTex Laboratories, GenCure, and The Blood & Tissue Center Foundation. The organization provides lifesaving therapies to patients and supports advances in advanced therapies, focusing on blood, cell, and tissue products, testing services, and the development of new therapies.

Blood Centers of America (BCA) is the largest blood supply network in the United States, comprising over 60 independent community blood centers that collectively distribute approximately 50% of the nation's blood supply. BCA supports member organizations through supply chain solutions, donor recruitment, advocacy, disaster response, and purchasing power. In addition to providing whole blood, red blood cells, platelets, plasma, cells, and tissues for therapeutic, diagnostic, research, and advanced therapy applications, BCA and its network are engaged in the development and delivery of advanced therapies including cell and gene therapy starting materials, processing, and manufacturing. BCA actively mobilizes resources in response to national emergencies, pandemics, and technological advances in donor experience and biotherapeutics.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Caleo Biotechnologies develops advanced human tissue models to enable more predictive and clinically relevant preclinical research, with a focus on fibrotic and inflammatory diseases. Their core platform integrates epithelial, immune, and mesenchymal/stromal compartments into self-organizing, patient-derived 3D tissue models. These models are used to study disease mechanisms, evaluate drug responses, and de-risk therapy development by capturing patient-specific biology and microenvironmental interactions. Caleo also combines these systems with molecular analysis and scalable, AI-driven analytics to support drug discovery and translational research.

Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.

CellBios is a biotechnology company specializing in the design, development, and manufacturing of single-use bioprocessing and medical device solutions for healthcare, biotechnology, and regenerative medicine sectors. The company operates GMP and ISO-certified cleanroom facilities, offering a comprehensive portfolio of cryopreservation products, bioreactors, fluid management systems, advanced packaging, and specialty devices. By leveraging expertise in extrusion, molding, assembly, sterilization, quality control, and regulatory compliance, CellBios provides customized, scalable solutions to support blood transfusion, cell and gene therapy, biologics manufacturing, and clinical workflows.

Ceres Nanosciences, Inc. is a privately held company based in Northern Virginia, specializing in the development and commercialization of Nanotrap® hydrogel particle technology. Their mission is to deliver innovative products powered by Nanotrap Technology to address life science needs and provide better patient outcomes. Ceres' products enable the capture, concentration, and preservation of low-abundance analytes from diverse biological and environmental samples, supporting applications in diagnostics, research, and public health surveillance. The company is ISO 9001:2015 certified and collaborates with leading research institutions, public health agencies, and industry partners to advance global health security and biosecurity. Ceres has established a national network of Wastewater-based Epidemiology Centers of Excellence and has received significant funding from the NIH RADx initiative and other organizations to expand its impact in underserved communities. Their technology is widely adopted for wastewater-based epidemiology, proteomics, and nucleic acid analysis, with a strong focus on supporting public health monitoring, early detection of infectious diseases, and environmental bio-surveillance.

Chariot Biosciences develops next-generation cell and gene therapies for chronic diseases, focusing on innovative, long-lasting solutions that minimize the need for frequent injections. The company's proprietary platform is based on engineered symbiotic microbes designed to provide sustained delivery of therapeutic proteins and peptides after a single injection. Chariot targets chronic conditions such as Gaucher disease, diabetes, and cancer, aiming to improve patient adherence, reduce logistical challenges, and replace standard frequent biologic dosing.

ClearCure Biosciences is a clinical-stage biopharmaceutical company focused on developing non-toxic, first-in-class and best-in-class therapies for cancer, infectious diseases, sepsis, neurological diseases, and cardiovascular conditions. The company emphasizes drugging challenging targets, leveraging proprietary small molecules, nanotechnology, new oncology cell therapies, new transdermal drug delivery technology, AI and omics-driven approaches, and digital health solutions to address serious unmet medical needs. The company is currently seeking collaborators and partnerships.

Commense Bio is a biopharmaceutical company focusing on developing genetically engineered bacterial therapeutics for invasive infections. With a proprietary technology platform, the company is advancing live biotherapeutic products (LBPs) addressing various infectious diseases including MRSA, recurrent UTIs, cystic fibrosis-associated infections, and more. Their innovations center around gene-edited bacteria and microbiome substitution—with a single, prescription-only application administered dermally or nasally—as a novel, non-antibiotic approach against antimicrobial resistance. The team includes experience in drug development, commercialization, and scientific research.

Cook MyoSite, a subsidiary of Cook Group, has been advancing human muscle cell technology since 2002. Operating under ISO 9001:2015-certified quality standards, we specialize in primary human skeletal muscle-derived cells and fibro-adipogenic progenitors sourced from healthy donors and individuals with neuromuscular, metabolic, and rare disorders. Our offerings include custom cell procurement, specialized media formulations, and contract manufacturing services—supporting both academic research and clinical development in regenerative medicine. Beyond research tools, Cook MyoSite is pioneering autologous muscle-derived cell therapies. Our investigational product, iltamiocel, is currently in a Phase III clinical trial for fecal incontinence, demonstrating our commitment to translating cell-based science into real-world solutions. With expertise in GMP manufacturing, analytical testing, and tailored partnerships, we empower collaborators to accelerate innovation in musculoskeletal and neuromuscular health worldwide.

Cooper University Health Care is a regional academic health system recognized for comprehensive clinical services, advanced multidisciplinary care, specialized surgery, and robust research in South Jersey. It provides integrated healthcare across general and specialty domains, including cancer, neurosciences, cardiology, trauma, genetics, addiction medicine, and complex surgical procedures, supported by leading technologies and a network of modern facilities.

CureLab Veterinary is a biotechnology company focused on the development of gene-based therapies targeting cancer and chronic inflammatory diseases in companion animals, such as dogs, cats, and horses. Utilizing advances in comparative medicine and translational immunology, the company applies a plasmid-based platform to stimulate anti-cancer immune responses, modulate tumor microenvironments, and mitigate chronic inflammation. Clinical research leverages academic partnerships and a robust intellectual property portfolio, pursuing efficient regulatory approval pathways in major markets, including the US and Europe. Recent studies suggest broader applications in pain management and cross-species translational potential.

Diadem Biotherapeutics is a biotechnology company focused on developing first- and best-in-class therapeutics by engineering extracellular vesicles to modulate immune responses. Their mission is to innovate beyond existing solutions to address unmet medical needs, leveraging expertise in immunology, bioengineering, and drug development. The company’s proprietary DECOSTAR™ platform enables precise costimulatory activation or repression of immune cells, targeting a range of diseases including cancer and autoimmunity.

FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.

The Institute for Biohealth Innovation (IBI) at George Mason University unites over 300 faculty and thousands of students across 34 departments to advance human health and well-being through innovative research. The IBI focuses on major health challenges, including infectious diseases, cancer, brain and behavior, and cardiovascular health, collaborating with national and international partners to implement solutions that enhance health outcomes.